

Conflict of interest

Josh Siegel reports no relevant financial disclosures

Author GEN has received research support from NIMH, The Barnes Jewish Hospital Foundation, the Center for Brain Research in Depression, Center for Diabetes Translational Research, Institute for Clinical Translational Science and the McDonnell Center for Systems Neuroscience at Washington University School of Medicine, and has consulted for Alkermes. Author NBF receives research support from the BJH Foundation and holds patents on the use of clonidine to improve the tolerability of ketamine. Author EJM receives grant/research support from NIA, NCCIH, OBSSR, FDA, PCORI, McKnight Brain Research Foundation, Takeda, Alkermes, Aptinyx, Johnson & Johnson, and Lundbeck and previously Roche and the Sidney R. Baer Foundation and he has consulted for Janssen Pharmaceuticals and Jazz Pharmaceuticals.

Authors JSS, BJP, BMA, EDK, JAS, AZS, and MDY all report no relevant financial disclosures.